Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome –Positive Acute Lymphoblast Leukemia: A Systematic Review

Relapse after stem cell transplantation for Philadelphia chromosome –positive (Ph+) acute lymphoblastic leukemia (ALL) remains a significant challenge. In this systematic review, we compare survival outcomes of second-generation tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib with first-generation TKI imatinib when these agents are used after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Ph+ ALL. In addition, we review the literature on TKI use to prevent relapse in patients who proceed to allo-HSCT beyond first complete response (>CR1).

Source: Biology of Blood and Marrow Transplantation - September 22, 2019 Category: Hematology Authors: Zabih Warraich, Pavan Tenneti, Theresa Thai, Anne Hubben, Hina Amin, Ali McBride, Sami Warraich, Abdul Hannan, Faiza Warraich, Navneet Majhail, Matt Kalaycio, Faiz Anwer Source Type: research